Overview

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1

Status:
Completed

Trial end date:
2021-09-23

Target enrollment:

Participant gender:

Summary

This study is a sub-study of the master protocol 205801 (NCT03739710). This sub study has assessed the clinical activity of novel regimen (Feladilimab plus Docetaxel) with SOC (Docetaxel) in participants with NSCLC.

Phase:

Phase 2

Details

Lead Sponsor:

GlaxoSmithKline

Collaborator:

iTeos Belgium SA

Treatments:

Docetaxel